射频消融术和^131I-肿瘤细胞核人鼠嵌合单抗治疗肺癌  

Radiofrequency ablation and Iodine-131 labeled nuclei of tumor cells chimeric monoclonal antibody radioimmunotherapy for the treatment of lung cancer

作　　者：张金山[1] 邓咏梅[1] 

机构地区：[1]广州医学院第三附属医院核医学科,510150

出　　处：《国际放射医学核医学杂志》2009年第3期159-163,共5页International Journal of Radiation Medicine and Nuclear Medicine

基　　金：广州市医药卫生科技一般引导项目（2007-YB-238）

摘　　要：射频消融（RFA）被认为是一种新型的肺癌病灶局部控制的微创治疗方法，具有方法操作简便、安全可靠、无全身不良反应、对肺癌有较高局部控制率等优点，但对于瘤体负荷较大的肿瘤病灶（如肿瘤直径3cm以上）治疗风险大、疗效欠佳。以变性和（或）坏死的肿瘤细胞核抗原作为结合靶点的新型放射免疫治疗即^131I标记的基因重组肿瘤细胞核单抗的肿瘤坏死治疗法为肿瘤的治疗提供了新途径，然而^131I-肿瘤细胞核人鼠嵌合单抗治疗肺癌的完全缓解率低。RFA扩大了肿瘤坏死区而有效增加了^131I-肿瘤细胞核人鼠嵌合单抗结合的靶点，故RFA联合^131I-肿瘤细胞核人鼠嵌合单抗治疗呵望明显提高对肺癌的治疗效果。Radiofrequency ablation （RFA）is an advanced, minimally invasive technique in the treatment of patients with lung cancer and has been found to be both safe and technically feasible with a high local efficacy, but for he size of the lesion is over 3.0 cm diameter there is less effective. Iodine-131-labeled nuclei of tumor cells chimeric monoclonal antibody, a novel radioimmunotherapy provided a new therapeutic approaches for lung cancer, but the complete response is low. For RFA can induce a mass complete tumor necrosis which greatly increase the targeting area for radioimmunotherapy, thus RFA followed by ^131I-nuclei of tumor cells chimeric monoclonal antibody adjuvant treatment may apparently improve the therapeutic efficacy of lung cancer, especially for tumors larger than 3.0 cm diameter.

关 键 词：肺肿瘤 碘放射性同位素 肿瘤细胞核人鼠嵌合单抗 射频消融 

分 类 号：R734.2[医药卫生—肿瘤]